ARK Diagnostics and Roche have announced a distribution agreement that will enable laboratories to integrate ARK’s methotrexate test into the Roche therapeutic drug monitoring (TDM) menu for its Cobas C 501 and Cobas C 502 clinical chemistry analyzers. The TDM Methotrexate Cobas C test kits are used to provide information to help healthcare professionals manage patients on cancer drug therapy.
“Roche is committed to providing a comprehensive menu of assays to support the varying needs of our customers. The addition of ARK’s methotrexate test to the Roche test menu will provide access for our customers to a specialized test for cancer drug monitoring with proven quality and performance,” says Randy Pritchard, senior vice president of Roche Professional Diagnostics. “This partnership demonstrates our commitment to finding innovative ways to offer a more comprehensive TDM portfolio.”
“Using the ‘partner channel’ approach to integrate our methotrexate test into the menu on Roche analyzers will enable many more clinical laboratories to expand the testing services they can offer to physicians for therapeutic drug monitoring,” says Robert O’Malley, ARK vice president of marketing, sales, and service. “We look forward to further collaboration with Roche in the field of drug monitoring tests.”
For more information, visit ARK Diagnostics and Roche.
